Investors

Translating Science into Solutions for Individualized Patient Care

Biotheranostics is a commercial stage molecular diagnostics company focused on cancer. We have two high-value proprietary and uniquely differentiated tests on the market, focused on critical areas of unmet medical needs. We are entering a rapid-growth phase with increasingly diversified growth drivers.

Contact Biotheranostics for more information on partnering with us:

molecular@biotheranostics.com

Client Services: (877) 886 6739

Fax: (858) 587 5874

In The News

Biotheranostics appoints F. Anthony Greco, M.D. as Medical Advisor for its CancerTYPE ID® molecular assay
Biotheranostics, Inc., announces announces F. Anthony Greco, MD as Medical Advisor for its CancerTYPE ID® test. CancerTYPE ID helps with identification of tumor type and subtype when a diagnosis remains unclear following standard diagnostic evaluation...
Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index® (BCI) being presented at the ASCO conference June 3rd, 2019 that further validates its ability to accurately predict which women
Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index® (BCI) being presented at the ASCO conference June 3rd, 2019 that further validates its ability to accurately predict which women…
Breast Cancer Index® Now Covered by Medicare for a Broader Group of Post-Menopausal Patients Considering Extended Endocrine Therapy
Biotheranostics, Inc., announces expanded Medicare coverage for its Breast Cancer Index® test under a new Local Coverage Determination [(LCD) L37822], effective today...
Breast Cancer Index® Receives Expanded Medicare Coverage Under a New Local Coverage Determination
Biotheranostics, Inc., announces its Breast Cancer Index (BCI) test has been issued a new Medicare Local Coverage Determination [(LCD) L37822] by Noridian, effective April 16, 2019...
View All